Dana-Farber Cancer Institute | Strategic Alliance Partners

May 30, 2025

Paul G. Richardson, MD, discusses the activity of quadruplet regimens containing daratumumab or isatuximab in patients with 1q-amplified multiple myeloma.

May 30, 2025

Here is your snapshot of all therapeutic options that were approved by the FDA in May 2025 spanning tumor types.

May 27, 2025

Paolo Tarantino, MD, PhD, discusses the need for prospective clinical trials to identify treatments for HER2+ breast cancer following progression on T-DXd.

May 27, 2025

Dana-Farber researchers unveil insights into aggressive pediatric brain tumors, paving the way for targeted therapies and improved patient outcomes.

May 25, 2025

The top 5 OncLive videos of the week cover insights in HER2+ breast cancer, myeloma, pancreatic cancer, prostate cancer, and sarcoma.

May 23, 2025

Yufei Wang, PhD, discusses how the metastasis of ccRCC could rewire the tumor microenvironment and lead to increased immunosuppression and fibrosis.

May 19, 2025

Elena Maroto-Martin, PhD, discusses early efficacy data with an MZB1-targeted TCR-like CAR T-cell therapy in multiple myeloma and Waldenström macroglobulinemia.

May 16, 2025

Paolo Tarantino, MD, PhD, discusses potentially practice-changing breast cancer research that will be presented at the 2025 ASCO Annual Meeting.

May 16, 2025

Elena Maroto-Martin, PhD, discusses the rationale for developing TCR-like CAR T-cell therapy in multiple myeloma and other hematologic malignancies.

May 12, 2025

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

May 05, 2025

Dana-Farber Cancer Institute opened the Ning Zhao & Ge Li Simulation Center, which is devoted exclusively to ambulatory oncology care.

May 01, 2025

Elizabeth Lee, MD, discusses the need for FRα-targeted therapies with differing payloads for patients with platinum-resistant ovarian cancer.

April 30, 2025

Erica Maria Pimenta, MD, PhD, discusses a study investigating potential defects in molecular pathways involved in adipocyte-specific differentiation

April 29, 2025

Glenn J. Hanna, MD, discusses the efficacy of elraglusib plus chemotherapy with or without immunotherapy in patients with advanced salivary gland cancer.

April 26, 2025

Penpulimab gets green light from FDA for nasopharyngeal carcinoma, sacituzumab govitecan combination boosts PFS in TNBC, and more.

April 25, 2025

Experts from across oncology specialties highlight research being presented at the 2025 AACR Annual Meeting.

April 25, 2025

Jennifer Chan, MD, MPH, highlights the significance of the FDA approval of cabozantinib for the treatment of patients with pNET and epNET.

April 23, 2025

Investigators found that the cancer-controlling effects of immune checkpoint inhibitors continue even after treatment is stopped due to immune-related adverse events in patients with advanced NSCLC.

April 21, 2025

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.

April 20, 2025

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, myelofibrosis, breast cancer, and sarcoma.